CD206-Targeting Compounds for Macrophage Cyto-State Alteration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 are inadequate in targeting the specific cellular processes mediated by macrophages, particularly in later disease stages where macrophages drive a thrombolytic cascade affecting multiple organs, and there is a lack of effective prophylactic antiviral therapies.
Innovation Solution
Development of compounds and compositions that target CD206-expressing macrophages using dextran-based molecular entities with C-type lectin targeting moieties, allowing for therapeutic agent delivery and diagnostic labeling to alter cyto-states in cells, specifically designed for treating COVID-19 by administering these compounds to affected cells in the lungs and liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (hydroxychloroquine, azithromycin, remdesivir, steroids) are used for COVID-19, then symptom management is provided, but the treatments are non-specific and fail to target the underlying cellular processes mediated by macrophages
Solution Approach 1:
The patent employs C-type lectin receptors (specifically CD206) as intermediary targets on macrophage surfaces. The therapeutic compounds bind to these receptors, mediating the delivery of therapeutic effects specifically to infected macrophages. This intermediary approach allows conventional treatments to be enhanced with targeted delivery mechanisms, addressing the lack of specificity while maintaining the beneficial effects of existing therapies.
Solution Approach 2:
The invention applies local quality by directing therapeutic effects specifically to macrophages expressing CD206 in affected tissues (lungs, liver, other organs). Rather than systemic non-specific treatment, the compounds concentrate their action on the specific cell type and location where COVID-19 pathology occurs, creating localized therapeutic quality that addresses the contradiction between effectiveness and specificity.
2Object-affected harmful factors
If macrophages are targeted in later disease stages, then the thrombolytic cascade affecting multiple organs can be addressed, but the disease has already progressed to severe stages
Solution Approach 1:
The patent enables preliminary action by providing compounds that can be administered early in the disease course to prevent macrophage-mediated thrombolytic cascade activation. By targeting CD206-expressing macrophages before they drive the thrombolytic cascade, the treatment can prevent severe multi-organ involvement rather than merely addressing it after progression. This preliminary targeting approach addresses both the harmful factors and the time loss contradiction.
3Adaptability or versatility
If C-type lectin receptors are used as therapeutic targets, then specific cellular pathways can be modulated, but the complexity of identifying and targeting these receptors increases
Solution Approach 1:
The patent exploits the universality of C-type lectin receptors, particularly CD206, which are expressed on macrophages across different tissues and disease stages. By targeting this universal receptor, a single compound design can address multiple pathological processes (viral entry, macrophage activation, thrombolytic cascade) across different organs, reducing the complexity that would arise from developing separate targeting mechanisms for each pathway or tissue.
Data Source
AI summary
A compound for altering cyto-states of cells that express C-type lectin receptors. The compound may be useful in the treatment of various diseases and/or conditions, including immune apathy and/or immune evasion caused by the onset of solid tumors. Disclosed herein are specific embodiments of the compound that target CD206 (a type of C-type lectin receptor) to induce suicidalness in the cell. The compound includes tilmanocept, which may be fluorinated and/or may contain chelated cations. Also disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.